PD-1阻害薬及びPD-L1阻害薬の世界市場動向：競争状況、パイプライン及び市場分析...市場調査レポートについてご紹介

Introduction 2

Executive Summary 3

Programmed Death 1 (PD-1) 9
Programmed Death Ligand 1 (PD-L1) 10
Role of PD-1 and PD-L1 pathways 11
MOA of PD-1 and PD-L1 inhibitors 12
Significance of PD-1 and PD-L1 inhibitors 13
PD-1 and PDL-1 Active Therapy Areas & Epidemiology 14
Metastatic Renal Cell Carcinoma 14
Epidemiology 14
Squamous Cell Carcinomas of the Head and Neck 15
Epidemiology 15
Metastatic Colorectal Cancer 16
Epidemiology 16
Gastric Cancer 17
Epidemiology 17
Biomarkers – PD-1 and PD-L1 inhibitors 18

Market Overview 20
Comparative Analysis of Pipeline & Marketed Drugs 20
Marketed Product of PD-1 and PD-L1 drugs -Overview 21
Marketed Drug Candidate Profiles 22
Pembrolizumab 22
Nivolumab 23
Marketed Drugs Sales 24
Details of patent expiry of marketed drugs 25
Current and Future Market for PD and PD-L1 inhibitors: 26
Challenges and Barriers associated with use of PD and PD-L1 inhibitors: 28
Anti–PD-1 Agents in Non–Small Cell Lung Cancer 29
Anti–PD-1 Agents in Triple-Negative Breast Cancer 29
Anti–PD-1 Agents in Melanoma 29
Combination therapy 30

Pipeline Therapeutics 31
An overview of pipeline products 31
Therapeutics under Development by MOA 33
Therapeutics under Development by Indication 34
Therapeutics under Development by Companies 37

Drug Candidate Profiles 39

Therapeutic Assessment of pipeline 72
Therapeutics under Development by Product Type 72
Therapeutics under Development by Phases for Monotherapy 73
Therapeutics under Development by Phases for Combination Products 74
Therapeutics under Development by Route of Administration of Monotherapy 75
Therapeutics under Development by Route of Administration of Combination Products 76
Industry Financial- Company Profiles 77

SWOT Analysis 82
Market Research Methodology 83
Research Design 83
Contact Us 85
Disclaimer 85

[List of Tables]
Table 1: Number of Products Under Development and Marketed forPD-1 and PD-L1 Drugs , 2015 20
Table 2: PD-1 Marketed Drugs, 2015 21
Table 3: Sales of Marketed drugs, 2015 24
Table 4: Details of patent expiry of marketed molecules, 2015 25
Table 5: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2015 32
Table 6: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs by MOA, 2015 33
Table 7: Number of Products Under Development for PD-1 and PD-L1 Drugs by Indication, 2015 34
Table 8: Number of Products under Development by Companies, 2015 37
Table 9: Number of Products Under Development forPD-1 and PD-L1 Drugs, 2015 72
Table 10: Number of Products Under Development forPD-1 and PD-L1 inhibitor Drugs (Molecule Type Single), 2015 73
Table 11: Number of Products Under Development forPD-1 and PD-L1 Drugs (Combination Type Product), 2015 74
Table 12: Number of Products under Development by Route of Administration Single Type Product, 2015 75
Table 13: Number of Products under Development by Route of Administration Combination Type Product, 2015 76

[List of figures]
Figure 1: T cell interaction with cancer 9
Figure 2: PD-L1/PD-1 Pathway 11
Figure 3: MOA of PD-1 and PD-L1 12
Figure 4: Number of Products under Development and Marketed for PD-1 and PD-L1 Drugs, 2015 20
Figure 5: Sales of marketed drugs, 2015 24
Figure 6: Details of patent expiry of marketed molecules, 2015 25
Figure 7: Number of Products under Development for PD-1 and PD-L1 inhibitors Drugs, 2015 31
Figure 8 Products under Development by MOA, 2015 33
Figure 9 Products under Development by Indication, 2015 34
Figure 10: Number of Products by Product Type for PD-1 and PD-L1Inhibitor Drugs, 2015 72
Figure 11: Number of Products under Development for PD-1 and PD-L1 inhibitor Drugs (Molecule Type Single), 2015 73
Figure 12: Number of Products under Development for PD-1 and PD-L1 Drugs (Combination Type Product), 2015 74
Figure 13: Percentage of pipeline drugs by Route of Administration of Single Type Product (%), 2015 75
Figure 14: Percentage of pipeline drugs by Route of Administration of Combination Type Product (%), 2015 76